MedTrace Logo

Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3

NCT04820010 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-04-27

No results posted yet for this study

Summary

Purpose: To evaluate the clinical outcome of patients with refractory Neurotrophic Keratopathy (NK) in stages 2 and 3 treated with topical insulin.

Methods: A retrospective, observational analysis of eyes with NK in stages 2 and 3 refractory to standard medical and/or surgical treatment which were treated with topical insulin. Topical insulin (1 unit per mL) was applied 4 times a day; treatment was continued until persistent epithelial defect (PED) or ulcer resolved and then tapered accordingly. The primary outcome of the study was the complete resolution of the PED or ulcer. Best-corrected visual acuity (BCVA), days until complete resolution as well as anterior segment photographs were obtained.

Conditions

Interventions

DRUG

Topical Insulin

Patients were administered eyedrops enriched with insulin

Sponsors & Collaborators

  • Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.

    lead OTHER_GOV

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-11-01
Completion
2020-11-01

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04820010 on ClinicalTrials.gov